A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Cardó Vila, Marina ^a   Zurita, Amado J ^a   Giordano, Ricardo J ^a   Sun, Jessica ^a   Rangel, Roberto ^a   Guzman Rojas, Liliana ^a   Anobom, Cristiane D ^b   Valente, Ana P ^b   Almeida, Fábio C L ^b   Lahdenranta, Johanna ^a   Kolonin, Mikhail G ^a   Arap, Wadih ^a   Pasqualini, Renata ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINYLGLYCYLARGINYLARGINYLALANYLGLYCYLGLYCYLSERYLCYSTEINE; INTERLEUKIN 11; INTERLEUKIN 11 RECEPTOR ALPHA; POLYPEPTIDE; SERINE; STAT3 PROTEIN; UNCLASSIFIED DRUG; LIGAND; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN MOTIF; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; CHEMISTRY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR MIMICRY; NEOPLASM; PROTEIN BINDING;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BINDING SITES; CELL PROLIFERATION; HUMANS; INTERLEUKIN-11; INTERLEUKIN-11 RECEPTOR ALPHA SUBUNIT; LIGANDS; MOLECULAR MIMICRY; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN BINDING; STAT3 TRANSCRIPTION FACTOR;

EID: 55149092968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003452     Document Type: Article

References (63)

1. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, et al. (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8: 121-127.
2. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, et al. (2004) Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64: 435-439.
3. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
4. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038.
5. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, et al. (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17: 768-774.
6. Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7: 1249-1253.
7. Marchiò S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, et al. (2004) Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 5: 151-162.
8. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W (2004) Reversal of obesity by targeted ablation of adipose tissue. Nat Med 10: 625-632.
9. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, et al. (2004) Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275-284.
10. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, et al. (2006) A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125: 385-398.
11. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
12. Campbell CL, Jiang Z, Savarese DM, Savarese TM (2001) Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 158: 25-32.
13. Du X, Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89: 3897-3908.
14. http://www.fda.gov/cder/biologics/products/opregen112597.htm. Center for Drug Evaluation and Research. U.S. Food and Drug Administration, Drug Information.
15. Bravo J, Heath JK (2000) Receptor recognition by gp130 cytokines. Embo J 19: 2399-2411.
16. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20.
17. Tacken I, Dahmen H, Boisteau O, Minvielle S, Jacques Y, et al. (1999) Definition of receptor binding sites on human interleukin-11 by molecular modeling-guided mutagenesis. Eur J Biochem 265: 645-655.
18. Czupryn MJ, McCoy JM, Scoble HA (1995) Structure-function relationships in human interleukin-11. Identification of regions involved in activity by chemical modification and site-directed mutagenesis. J Biol Chem 270: 978-985.
19. Czupryn M, Bennett F, Dube J, Grant K, Scoble H, et al. (1995) Alanine-scanning mutagenesis of human interleukin-11: identification of regions important for biological activity. Ann N Y Acad Sci 762: 152-164.
20. Harmegnies D, Wang XM, Vandenbussche P, Leon A, Vusio P, et al. (2003) Characterization of a potent human interleukin-11 agonist. Biochem J 375: 23-32.
21. Barton VA, Hudson KR, Heath JK (1999) Identification of three distinct receptor binding sites of murine interleukin-11. J Biol Chem 274: 5755-5761.
22. Dahmen H, Horsten U, Kuster A, Jacques Y, Minvielle S, et al. (1998) Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions. Biochem J 331: 695-702.
23. Kurth I, Horsten, U, Pflanz S, Dahmen H, Kuster A, et al. (1999) Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes. J Immunol 162: 1480-1487.
24. Schleinkofer K, Dingley A, Tacken I, Federwisch M, Muller-Newer G, et al. (2001) Identification of the domain in the human interleukin-11 receptor that mediates ligand binding. J Mol Biol 306: 263-274.
25. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300: 2101-2104.
26. Muller-Newen G (2003) The cytokine receptor gp130: faithfully promiscuous. Sci STKE PE40.
27. Hermanns HM, Muller-Newen G, Heinrich PC, Haan S (2005) Bow to your partner for signaling. Nat Struct Mol Biol 12: 476-478.
28. Schroers A, Hecht O, Kallen, KJ, Pachta M, Rose-John S, et al. (2005) Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci 14: 783-790.
29. Grotzinger J, Kernebeck T, Kallen KJ, Rose-John S (1999) IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem 380: 803-813.
30. Giordano RJ, Anobom CD, Cardó-Vila M, Kalil J, Valente AP, et al. (2005) Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. Chem Biol 12: 1075-1083.
31. Valente AP, Miyamoto CA, Almeida FC (2006) Implications of protein conformational diversity for binding and development of new biological active compounds. Curr Med Chem 13: 3697-3703.
32. Pires JR, Taha-Nejad F, Toepert F, Ast T, Hoffmuller U, et al. (2001) Solution structures of the YAP65 WW domain and the variant L30 K in complex with the peptides GTPPPPYTVG, N-(n-octyl)-GPPPY and PLPPY and the application of peptide libraries reveal a minimal binding epitope. J Mol Biol 314: 1147-1156.
33. Cruzeiro-Silva C, Gomes-Neto F, Tinoco LW, Cilli EM, Barros PV, et al. (2007) Structural biology of membrane-acting peptides: conformational plasticity of anticoccidial peptide PW2 probed by solution NMR. Biochim Biophys Acta 1768: 3182-3192.
34. Henzler-Wildman K, Kern D (2007) Dynamic personalities of proteins. Nature 450: 964-972.
35. Henzler-Wildman KA, Thai V, Lei M, Ott M, Wolf-Watz M, et al. (2007) Intrinsic motions along an enzymatic reaction trajectory. Nature 450: 838-844.
36. Fourcin M, Chevalier S, Lebrun JJ, Kelly P, Pouplard A, et al. (1994) Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor. Eur J Immunol 24: 277-280.
37. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W (2003) Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep 33: 20-26.
38. Pentz RD, Cohen CB, Wicclair M, DeVita MA, Flamm AL, et al. (2005) Ethics guidelines for research with the recently dead. Nat Med 11: 1145-1149.
39. Somers W, Stahl M, Seehra JS (1997) 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. Embo J 16: 989-997.
40. McDonald NQ, Panayotatos N, Hendrickson WA (1995) Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing. Embo J 14: 2689-2699.
41. Panayotatos N, Radziejewska E, Acheson A, Somogyi R, Thadani A, et al. (1995) Localization of functional receptor epitopes on the structure of ciliary neurotrophic factor indicates a conserved, function-related epitope topography among helical cytokines. J Biol Chem 270: 14007-14014.
42. Simpson, RJ, Hammacher A, Smith DK, Matthews JM, Ward LD (1997) Interleukin-6: structure-function relationships. Protein Sci 6: 929-955.
43. Hudson KR, Vernallis AB, Heath JK (1996) Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists. J Biol Chem 271: 11971-11978.
44. Ciapponi L, Graziani R, Paonessa G, Lahm A, Ciliberto G, et al. (1995) Definition of a composite binding site for gp130 in human interleukin-6. J Biol Chem 270: 31249-31254.
45. Chow D, He X, Snow AL, Rose-John S, Garcia KC (2001) Structure of an extracellular gp130 cytokine receptor signaling complex. Science 291: 2150-2155.
46. Kallen KJ, Grotzinger J, Lelievre E, Vollmer P, Aasland D, et al. (1999) Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6. J Biol Chem 274: 11850-11867.
47. Boulanger MJ, Cho DC, Brevnova E, Martick M, Sandford G, et al. (2004) Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. J Mol Biol 335: 641-654.
48. Lebeau B, Montero Julian FA, Wijdenes J, Muller-Newen G, Dahmen H, et al. (1997) Reconstitution of two isoforms of the human interleukin-11 receptor and comparison of their functional properties. FEBS Lett 407: 141-147.
49. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, et al. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458-464.
50. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, et al. (1996) Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 273: 464-471.
51. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, et al. (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276: 1696-1699.
52. Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, et al. (1998) An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol 5: 993-1004.
53. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, et al. (2003) Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 12: 1239-1250.
54. Pillutla RC, Hsiao KC, Beasley JR, Brandt J, Ostergaard S, et al. (2002) Peptides identify the critical hotspots involved in the biological activation of the insulin receptor. J Biol Chem 277: 22590-22594.
55. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, et al. (2002) Structure of the extracellullar domains of the human interleukin-6 receptor alpha-chain. Proc Natl Acad Sci U S A 99: 15959-15964.
56. Schuster B, Meinert W, Rose-John S, Kallen KJ (2003) The human interleukin-6 (IL-6) receptor exists as a preformed dimer in the plasma membrane. FEBS Lett 538: 113-116.
57. Greiser JS, Stross C, Heinrich PC, Behrmann I, Hermanns HM (2002) Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling. J Biol Chem 277: 26959-26965.
58. Muller-Newen G, Kuster A, Wijdenes J, Schaper F, Heinrich PC (2000) Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies. J Biol Chem 275: 4579-4586.
59. Skiniotis G, Boulanger MJ, Garcia KC, Walz T (2005) Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol 12: 545-551.
60. Smith GP, Scott JK (1993) Libraries of peptides and proteins displayed on filamentous phage. Meth Enzymol 217: 228-257.
61. Piotto M, Saudek V, Sklenar V (1992) Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J Biomol NMR 2: 661-665.
62. Bax A, Davis DG (1985) Mlev-17-Based Two-Dimensional Homonuclear Magnetization Transfer Spectroscopy. J Magn Reson 65: 355-360.
63. Sklenar V, Piotto M, Leppik R, Saudek V (1993) Gradient-tailored water suppression for H-1-N-15 Hsqe experiments optimized to retain full sensitivity. J Magn Reson Series A 102: 241-245.